| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
(2S,3R)-LP99 targets bromodomain and extra-terminal (BET) proteins, including BRD2, BRD3, BRD4, and BRDT. These proteins recognize acetylated lysine residues on histones and regulate gene transcription. By inhibiting BET bromodomains, the compound blocks the interaction between BET proteins and acetylated histones, leading to suppression of oncogene expression.
|
|---|---|
| ln Vitro |
(2S,3R)-LP99 (Compound 60) (0-100 µM) suppresses IL6 expression in LPS-stimulated (100 ng/mL) THP-1 cells [1].
In vitro, (2S,3R)-LP99 binds to BET bromodomains with high affinity as assessed by fluorescence polarization (FP) or AlphaScreen assays. It inhibits the proliferation of cancer cell lines that depend on BET protein function. The compound's activity may be evaluated in various cell lines including leukemia, lymphoma, and solid tumor cells. |
| ln Vivo |
No detailed in vivo activity data are available for (2S,3R)-LP99. As a BET bromodomain inhibitor, it would be expected to exhibit antitumor activity in vivo. Further studies are needed to characterize its pharmacokinetic properties, efficacy, and toxicity profile in animal models.
|
| Enzyme Assay |
BET bromodomain binding assays are performed using recombinant BRD2, BRD3, BRD4, or BRDT bromodomains. The protein is incubated with a fluorescently labeled acetylated histone peptide and varying concentrations of (2S,3R)-LP99. Fluorescence polarization is measured to determine the displacement of the peptide. IC50 values are calculated from competition curves.
|
| Cell Assay |
(2S,3R)-LP99 is evaluated in cancer cell lines such as MV-4-11 (leukemia), MM.1S (multiple myeloma), and others. Cells are cultured with the compound at various concentrations for 48-72 hours. Cell viability is measured using MTT or resazurin-based assays. IC50 values for growth inhibition are calculated. Effects on MYC expression and apoptosis are assessed.
|
| Animal Protocol |
(2S,3R)-LP99 would be evaluated in tumor-bearing mouse models (e.g., xenografts) to assess antitumor efficacy. The compound is formulated in suitable vehicles and administered via oral gavage or intraperitoneal injection. Tumor volume is measured over time. Pharmacokinetic parameters including plasma half-life, clearance, and tissue distribution are determined.
|
| References |
[1]. Clark PG, et al. LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angew Chem Int Ed Engl. 2015 May 18;54(21):6217-21.
|
| Molecular Formula |
C26H30CLN3O4S
|
|---|---|
| Molecular Weight |
516.052104473114
|
| Exact Mass |
515.164
|
| CAS # |
1808948-28-8
|
| Related CAS # |
1808951-93-0; 1808948-28-8;
|
| PubChem CID |
138991750
|
| Appearance |
White to off-white solid
|
| LogP |
3.5
|
| tPSA |
95.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
35
|
| Complexity |
939
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(S(N[C@@H]1CCC(=O)N(C2=CC3=C(C=C2)C(C)=CC(=O)N3C)[C@H]1C1=CC=C(Cl)C=C1)(=O)=O)C(C)C
|
| InChi Key |
LVDRREOUMKACNJ-GJZUVCINSA-N
|
| InChi Code |
InChI=1S/C26H30ClN3O4S/c1-16(2)15-35(33,34)28-22-11-12-24(31)30(26(22)18-5-7-19(27)8-6-18)20-9-10-21-17(3)13-25(32)29(4)23(21)14-20/h5-10,13-14,16,22,26,28H,11-12,15H2,1-4H3/t22-,26+/m1/s1
|
| Chemical Name |
N-[(2S,3R)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9378 mL | 9.6890 mL | 19.3780 mL | |
| 5 mM | 0.3876 mL | 1.9378 mL | 3.8756 mL | |
| 10 mM | 0.1938 mL | 0.9689 mL | 1.9378 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|